Please use this identifier to cite or link to this item:
https://doi.org/10.1586/14737159.6.3.365
DC Field | Value | |
---|---|---|
dc.title | Congenital long QT syndromes: Clinical features, molecular genetics and genetic testing | |
dc.contributor.author | Ching, C.-K. | |
dc.contributor.author | Tan, E.-C. | |
dc.date.accessioned | 2014-11-26T07:50:26Z | |
dc.date.available | 2014-11-26T07:50:26Z | |
dc.date.issued | 2006 | |
dc.identifier.citation | Ching, C.-K., Tan, E.-C. (2006). Congenital long QT syndromes: Clinical features, molecular genetics and genetic testing. Expert Review of Molecular Diagnostics 6 (3) : 365-374. ScholarBank@NUS Repository. https://doi.org/10.1586/14737159.6.3.365 | |
dc.identifier.issn | 14737159 | |
dc.identifier.uri | http://scholarbank.nus.edu.sg/handle/10635/109832 | |
dc.description.abstract | Congenital long QT syndrome (LQTS) is a primary electrical disease characterized by a prolonged QT interval in the surface electrocardiogram and increased predisposition to a typical polymorphic ventricular tachycardia, termed Torsade de Pointes. Most patients with LQTS are asymptomatic and are diagnosed incidentally based on an electrocardiogram. Symptomatic patients may suffer from severe cardiac events, such as syncope and/or sudden cardiac death. Autosomal dominant forms are caused by heterozygous mutations in genes encoding the components of the ion channels. The autosomal recessive form with congenital deafness is also known as Jervell and Lang-Nielsen syndrome. It is caused by homozygous mutations or certain compound heterozygous mutations. Depending on the genetic defects, there are differences in the age of onset, severity of symptoms, and number of cardiac events and event triggers. With advances in gene technology, it is now feasible to perform genetic testing for LQTS, especially for those with family history. Identification of the mutation will lead to better management of symptoms and more targeted treatment, depending on the underlying genetic defect, resulting in a reduction of mortality and cardiac events. © 2006 Future Drugs Ltd. | |
dc.description.uri | http://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1586/14737159.6.3.365 | |
dc.source | Scopus | |
dc.subject | Cardiac arrhythmia | |
dc.subject | Channelopathy | |
dc.subject | Genetic testing | |
dc.subject | Mutation | |
dc.subject | QT interval | |
dc.subject | Sudden cardiac death | |
dc.type | Review | |
dc.contributor.department | PSYCHOLOGICAL MEDICINE | |
dc.description.doi | 10.1586/14737159.6.3.365 | |
dc.description.sourcetitle | Expert Review of Molecular Diagnostics | |
dc.description.volume | 6 | |
dc.description.issue | 3 | |
dc.description.page | 365-374 | |
dc.description.coden | ERMDC | |
dc.identifier.isiut | 000237916000009 | |
Appears in Collections: | Staff Publications |
Show simple item record
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.